BioNTech, a German pharmaceutical company, has announced plans to produce a malaria vaccine based on messenger RNA (mRNA). Malaria is a life-threatening disease that affects millions of people worldwide, particularly in Africa.
The business, which worked with Pfizer to develop the first COVID-19 vaccine approved in the United States, said it plans to start clinical trials by the end of 2022.
According to the firm, the World Health Organization (WHO), the European Commission, and other organizations were involved in the early design stages of the new vaccine. Global organizations have also contributed assistance in identifying and establishing the essential infrastructure.
The corporation also stated that it would manufacture the possible vaccine in African facilities, either with licensed partners or on its own. The goal, according to Mr. Sahin, BioNTech CEO, is to produce “sustainable solutions for and with the people of Africa”.
The new vaccine is being developed as the globe continues to battle with the COVID-19 epidemic, which has claimed the lives of more than four million people worldwide.